Corvus Pharmaceuticals has faced volatility due to mixed clinical data and given the current valuation and market ...

Stock analysts at HC Wainwright lifted their FY2025 earnings per share estimates for shares of Corvus Pharmaceuticals in a ...

Corvus Pharmaceuticals suffered lately, especially after it announced in December 2024 its early AD data. Check out why I ...

Q4 2024 Earnings Call Transcript March 25, 2025 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is ...

Corvus Pharmaceuticals Inc. (($CRVS)) has held its Q4 earnings call. Read on for the main highlights of the call. The recent earnings call of ...

Oppenheimer raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $15 from $14 and keeps an Outperform rating on the shares after ...

Insiders who purchased Corvus Pharmaceuticals, Inc. ( NASDAQ:CRVS ) shares in the past 12 months are unlikely to ...

Reports as of December 31, Corvus had cash, cash equivalents and marketable securities of $52.M as compared to $27.1M as of December 31, 2023.

Corvus Energy, Bergen, Norway, recently announced that it has received type approval from Lloyd’s Register (LR) for its ...

On a per-share basis, the Burlingame, California-based company said it had a loss of 18 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by ...

Thank you for standing by and welcome to the Corvus Pharmaceuticals fourth-quarter and full-year 2024 business update and financial results conference call. (Operator Instructions) It is now my ...